title: Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib.
abstract: Transarterial chemoembolization (TACE) has been the standard treatment modality in patients with intermediate stage hepatocellular carcinoma (HCC). Brivanib is an oral small molecular inhibitor of both vascular endothelial growth factor and fibroblast growth factor receptors. Herein, we reported that a 67-year-old patient with intermediate stage HCC achieved the complete remission after TACE combined with brivanib therapy. This finding potentially suggested the benefit of this combination therapy for HCC.
authors.forename: Jia
authors.initials: J
authors.lastname: Jia
authors.forename: Xingshun
authors.initials: X
authors.lastname: Qi
authors.forename: Wei
authors.initials: W
authors.lastname: Bai
authors.forename: Jie
authors.initials: J
authors.lastname: Yuan
authors.affiliation: Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
authors.forename: Guohong
authors.initials: G
authors.lastname: Han
mesh_terms: D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D016461:Chemoembolization, Therapeutic; D018450:Disease Progression; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D012074:Remission Induction; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D017468:Receptors, Fibroblast Growth Factor; D014227:Triazines; D042461:Vascular Endothelial Growth Factor A; C509922:brivanib; D000409:Alanine